Clinical experience with a software based tachycardia reversion pacemaker.
Current generation antitachycardia pacemakers suffer from limitations concerning detection and distinction of pathological tachycardia and also from the termination modes available. To overcome many of these limitations, a new device (Intermedics Intertach 262-12) has been developed, and has now been implanted in nine patients, all of whom had failed drug treatment. Since implantation, all patients have complete control of their arrhythmias, and only one now requires drug therapy.